Metabolic Profile and Negatively Association Between Insulin Resistance and Metastatic Incidence in Indonesian Primary Invasive Breast Cancer: A Cross-Sectional Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• IARC. Indonesia; 2020.
   Google Scholar
• Gondhowiardjo S, Christina N, Ganapati NPD, et al. Five-year cancer epidemiology at the national referral hospital: hospital-based cancer registry data in Indonesia. JCO Glob Oncol. 2021;(7):190–203. doi:10.1200/GO.20.00155
   PubMedGoogle Scholar
• Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2(4). doi:10.1093/jncics/pky062
   PubMed Web of Science ®Google Scholar
• Martín-Manzo MV, Lara C, Vargas-de-Leon C, et al. Interaction of breast cancer and insulin resistance on PD1 and TIM3 expression in peripheral blood CD8 T cells. Pathol Oncol Res. 2019;25(3):1233–1243. doi:10.1007/s12253-019-00610-7
   PubMed Web of Science ®Google Scholar
• Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:1–12. doi:10.1155/2012/789174
   Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578. doi:10.1016/S0140-6736(08)60269-X
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Key TJ, Peeters PHM, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer. 2006;118(11):2832–2839. doi:10.1002/ijc.21730
   PubMed Web of Science ®Google Scholar
• Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EGE, Jalving M. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. Cancer Treat Rev. 2015;41(4):376–384. doi:10.1016/j.ctrv.2015.02.007
   PubMed Web of Science ®Google Scholar
• Barba M, Sperati F, Stranges S, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol. 2012;23(7):1838–1845. doi:10.1093/annonc/mdr540
   PubMed Web of Science ®Google Scholar
• Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al. Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012;2012:1–8. doi:10.1155/2012/732027
   Google Scholar
• Pan K, Nelson RA, Wactawski-Wende J, et al. Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women: the women’s health initiative. JNCI. 2020;112(2):170–178. doi:10.1093/jnci/djz069
   PubMedGoogle Scholar
• Shi H, Zhou L, Yang S, Zhou H. The relationship between triglyceride and glycose (TyG) index and the risk of gynaecologic and breast cancers. Clin Nutr ESPEN. 2022;51:345–352. doi:10.1016/j.clnesp.2022.08.004
   PubMed Web of Science ®Google Scholar
• Son DH, Lee HS, Lee YJ, Lee JH, Han JH. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metabol Cardiovasc Dis. 2022;32(3):596–604. doi:10.1016/j.numecd.2021.11.017
   PubMed Web of Science ®Google Scholar
• Park HM, Lee HS, Lee YJ, Lee JH. The triglyceride–glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance. Diabetes Res Clin Pract. 2021;180:109042. doi:10.1016/j.diabres.2021.109042
   PubMed Web of Science ®Google Scholar
• Nam S, Park S, Park HS, Kim S, Kim JY, Kim S. Association between insulin resistance and luminal b subtype breast cancer in postmenopausal women. Medicine. 2016;95(9):e2825. doi:10.1097/MD.0000000000002825
   PubMed Web of Science ®Google Scholar
• Panigoro SS, Sutandyo N, Witjaksono F, et al. The association between triglyceride-glucose index as a marker of insulin resistance and the risk of breast cancer. Front Endocrinol. 2021:12. doi:10.3389/fendo.2021.745236
   Web of Science ®Google Scholar
• Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13(1):47. doi:10.1186/1472-6823-13-47
   PubMedGoogle Scholar
• World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. World Health Organization; 2000.
   Google Scholar
• Enderlein G, Lemeshow S, Hosmer DW, Klar J, Lwanga St K. Adequacy of sample size in health studies. Biometr J. 1991;33(4):504. doi:10.1002/bimj.4710330419
   Google Scholar
• Ferguson RD, Novosyadlyy R, Fierz Y, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res. 2012;14(1):R8. doi:10.1186/bcr3089
   PubMed Web of Science ®Google Scholar
• Amabile MI, Frusone F, De Luca A, et al. Locoregional surgery in metastatic breast cancer: do concomitant metabolic aspects have a role on the management and prognosis in this setting? J Pers Med. 2020;10(4):227. doi:10.3390/jpm10040227
   PubMed Web of Science ®Google Scholar
• Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012;94(10):2137–2142. doi:10.1016/j.biochi.2012.06.008
   PubMed Web of Science ®Google Scholar
• Samuel S, Varghese E, Kubatka P, Triggle C, Büsselberg D. Metformin: the answer to cancer in a flower? Current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer. Biomolecules. 2019;9(12):846. doi:10.3390/biom9120846
   PubMed Web of Science ®Google Scholar
• Kundaktepe BP, Durmus S, Cengiz M, et al. The significance of insulin resistance in nondiabetic breast cancer patients. J Endocrinol Metab. 2021;11(2):42–48. doi:10.14740/jem729
   Web of Science ®Google Scholar
• Chiefari E, Mirabelli M, La Vignera S, et al. Insulin resistance and cancer: in search for a causal link. Int J Mol Sci. 2021;22(20):11137. doi:10.3390/ijms222011137
   PubMed Web of Science ®Google Scholar
• Tahapary DL, Pratisthita LB, Fitri NA, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr. 2022;16(8):102581. doi:10.1016/j.dsx.2022.102581
   PubMedGoogle Scholar
• Ferroni P, Riondino S, Laudisi A, et al. Pretreatment insulin levels as a prognostic factor for breast cancer progression. Oncologist. 2016;21(9):1041–1049. doi:10.1634/theoncologist.2015-0462
   PubMed Web of Science ®Google Scholar
• Nath Das R, Karmakar S, Saha I, Sahoo RK, Medda SK, Kottapalli R. The glucose level linkages with breast cancer markers. Cancer Res Cell Therap. 2021;5(2):01–04. doi:10.31579/2640-1053/083
   Google Scholar
• Sun S, Sun Y, Rong X, Bai L. High glucose promotes breast cancer proliferation and metastasis by impairing angiotensinogen expression. Biosci Rep. 2019;39(6). doi:10.1042/BSR20190436
   Google Scholar
• Li C, Sun S, Tu Y, et al. High glucose accelerates tumor progression by regulating MEDAG-mediated autophagy levels in breast cancer. Int J Biol Sci. 2022;18(11):4289–4300. doi:10.7150/ijbs.70002
   PubMed Web of Science ®Google Scholar
• Raza U, Asif MR, Bin Rehman A, Sheikh A. Hyperlipidemia and hyper glycaemia in breast cancer patients is related to disease stage. Pak J Med Sci. 2018;34(1). doi:10.12669/pjms.341.14841
   Web of Science ®Google Scholar
• Buch K, Gunmalm V, Andersson M, Schwarz P, Brøns C. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-a systematic review. Cancer Med. 2019;8(1):238–245. doi:10.1002/cam4.1911
   PubMed Web of Science ®Google Scholar
• Cheung YM, Hoermann R, Van K, et al. Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer. Clin Endocrinol. 2023;98(2):190–201. doi:10.1111/cen.14839
   PubMed Web of Science ®Google Scholar
• Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–3989. doi:10.1172/JCI129186
   PubMed Web of Science ®Google Scholar
• Castela I, Morais J, Barreiros-Mota I, et al. Decreased adiponectin/leptin ratio relates to insulin resistance in adults with obesity. Am J Physiol. 2023;324(2):E115–E119. doi:10.1152/ajpendo.00273.2022
   Google Scholar
• Iwase T, Wang X, Shrimanker TV, Kolonin MG, Ueno NT. Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Res Treat. 2021;186(2):273–283. doi:10.1007/s10549-020-06092-5
   PubMed Web of Science ®Google Scholar
• Amin MN, Hussain MDS, Sarwar MDS, et al. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab Syndr. 2019;13(2):1213–1224. doi:10.1016/j.dsx.2019.01.041
   PubMed Web of Science ®Google Scholar
• Bhandari A, Zheng C, Sindan N, et al. COPB2 is up‐regulated in breast cancer and plays a vital role in the metastasis via N‐cadherin and Vimentin. J Cell Mol Med. 2019;23(8):5235–5245. doi:10.1111/jcmm.14398
   PubMed Web of Science ®Google Scholar
• Alwhaibi A, Verma A, Adil MS, Somanath PR. The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis. Pharmacol Res. 2019;145:104270. doi:10.1016/j.phrs.2019.104270
   PubMed Web of Science ®Google Scholar
• Jacob L, Kostev K, Rathmann W, Kalder M. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. J Diabetes Complications. 2016;30(6):1056–1059. doi:10.1016/j.jdiacomp.2016.04.003
   PubMed Web of Science ®Google Scholar
• Constantinou C, Mpatsoulis D, Natsos A, et al. The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations. J Lipid Res. 2014;55(7):1434–1447. doi:10.1194/jlr.M050047
   PubMed Web of Science ®Google Scholar
• Oh SH, Choi SY, Choi HJ, et al. The emerging role of xanthine oxidase inhibition for suppression of breast cancer cell migration and metastasis associated with hypercholesterolemia. FASEB J. 2019;33(6):7301–7314. doi:10.1096/fj.201802415RR
   PubMed Web of Science ®Google Scholar
• Cedó L, Reddy ST, Mato E, Blanco-Vaca F, Escolà-Gil JC. HDL and LDL: potential new players in breast cancer development. J Clin Med. 2019;8(6):853. doi:10.3390/jcm8060853
   PubMed Web of Science ®Google Scholar
• Liu YL, Qian HX, Qin L, Zhou XJ, Zhang B, Chen X. [Association of serum lipid profile with distant metastasis in breast cancer patients]. Zhonghua Zhong Liu Za Zhi. 2012;34(2):129–131. Chinese. doi:10.3760/cma.j.issn.0253-3766.2012.02.010
   PubMedGoogle Scholar
• Dias S, Cesário V, Coutinho D, et al. Hypercholesterolemia promotes the intravasation of breast tumor cells through an LDL-LDLR axis. Res Square. 2022. doi:10.21203/rs.3.rs-1760715/v1
   Google Scholar
• Li X, Li LZ, Tuan WY, et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis. 2018;17(1):91. doi:10.1186/s12944-018-0745-1
   PubMedGoogle Scholar
• Dieli‐Conwright CM, Wong L, Waliany S, Bernstein L, Salehian B, Mortimer JE. An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer. 2016;122(17):2646–2653. doi:10.1002/cncr.30104
   PubMed Web of Science ®Google Scholar
• Guinan EM, Connolly EM, Healy LA, Carroll PA, Kennedy MJ, Hussey J. The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer. Cancer Nurs. 2014;37(5):355–362. doi:10.1097/NCC.0b013e3182a40e6d
   PubMed Web of Science ®Google Scholar
• Hassan MA, Ibrahim I, Saeed MM, Hussien NN. Effect of chemotherapy on lipid profile and insulin resistance among post mastectomy women. J Pharm Negat Results. 2023;14. doi:10.47750/pnr.2023.14.02.23
   Google Scholar
• Madeddu C, Gramignano G, Floris C, Murenu G, Sollai G, Macciò A. Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. J Cell Mol Med. 2014;18(12):2519–2529. doi:10.1111/jcmm.12413
   PubMed Web of Science ®Google Scholar
• Barone I, Giordano C, Bonofiglio D, Andò S, Catalano S. The weight of obesity in breast cancer progression and metastasis: clinical and molecular perspectives. Semin Cancer Biol. 2020;60:274–284. doi:10.1016/j.semcancer.2019.09.001
   PubMed Web of Science ®Google Scholar
• Osman MA, Hennessy BT. Obesity correlation with metastases development and response to first-line metastatic chemotherapy in breast cancer. Clin Med Insights Oncol. 2015;9:CMO.S32812. doi:10.4137/CMO.S32812
   PubMedGoogle Scholar
• Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Res Treat. 2007;105(2):177–186. doi:10.1007/s10549-006-9442-2
   PubMed Web of Science ®Google Scholar
• Roy R, Yang J, Shimura T, et al. Escape from breast tumor dormancy: the convergence of obesity and menopause. Proce Natl Acad Sci. 2022;119(41). doi:10.1073/pnas.2204758119
   Web of Science ®Google Scholar
• Jung SY, Mancuso N, Papp J, Sobel E, Zhang ZF, Wei Q. Post genome-wide gene-environment interaction study: the effect of genetically driven insulin resistance on breast cancer risk using Mendelian randomization. PLoS One. 2019;14(6):e0218917. doi:10.1371/journal.pone.0218917
   PubMed Web of Science ®Google Scholar